Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Shijiazhuang Chengzhi Yonghua Display Material Co., Ltd.

Hebei University of Science and Technology

Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

Li Zhang

Lan Zhang

Yanhui Li

Dongmin Shen

Chunlei Li

Caixia Wang

Min Liang

Yongfeng Li

Xian Xiu

Guoliang Yun

Xing Zhang

Ming Li

Lei Zhao

Jinsong Meng

Hongru Gao

Yanli Dong

Wenmin Guo

Zaixing Li

Yali Huang

YanLi Dong

Jinxu Wang

Yuanyuan Huang

Huizhen Xing

Disclosed are aSDF-25 strain and applications thereof, which relate to the technical field of environmental microorganisms. TheSDF-25 strain has a strain preservation number of CGMCC No. 19272. TheSDF-25 strain can be applied to straw degradation. TheSDF-25 strain provided in the present solution can grow normally at 6 to 37° C. TheSDF-25 strain can secrete a large amount of carboxymethyl cellulase at 10 to 16° C., and still produce enzyme at 6° C. The highest enzymatic activity can reach 993.3 U/mL.

SDF-25 strain and application thereof

A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase may contain sulfobutyl ether cyclodextrin and an active compound.

Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt

The present invention discloses a compound of which a structural formula thereof is represented as the following formula: The compound disclosed by the present invention can be used as a liquid crystal compound and overcomes the problem that solubility of the traditional dibenzothiophene-class liquid crystals is poor, and thus can be better applied to the liquid crystal material field. The present invention further discloses a liquid crystal medium containing the compound and an application thereof.

Compound, liquid crystal medium containing the compound and application thereof

The present invention relates to a liposomal pharmaceutical preparation containing a multivalent ionic drug, a process for the preparation of the liposomal pharmaceutical preparation, and a use thereof in the treatment of diseases, in which the liposome has a size of about 30-80 nm, and the phospholipid bilayer has a phospholipid with a Tm higher than body temperature, so that the phase transition temperature of the liposome is higher than the body temperature.

Liposomal pharmaceutical preparation and method for manufacturing the same

A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase contains sulfobutyl ether cyclodextrin and active compound. Said sulfobutyl ether cyclodextrin is sulfobutyl ether &#x3b1;-cyclodextrin, sulfobutyl ether &#x3b2;-cyclodextrin, or sulfobutyl ether &#x3b3;-cyclodextrin.

Growing community of inventors

Hebei, China

Li Zhang